Celltrion inks deal worth $1.75B for cancer-based bispecific antibody

US-based biotech firm Abpro has announced a strategic partnership with Celltrion, a biopharmaceutical company headquartered in South Korea, for its cancer molecule ABP

102, an antibody therapy for patients suffering from HER2+ cancer, including breast, gastric, and pancreatic cancer. Through this global partnership, Abpro will receive payments from Celltrion of up to $1.75 billion, including an equity investment, development and commercial milestone payments and worldwide profit sharing. Celltrion will be in charge of the development of ABP 102 following the completion of in vitro studies by Abpro and will have worldwide commercialisation rights. HER2+ type cancer is implicated in up to 30 per cent of all cases in breast, gastric, pancreatic, and other forms of cancer. Abpro’s

ABP 102 molecule has shown preliminary data of better efficacy and less toxicity compared to other therapies treating the same indication.